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Abstract
Background: Although the lymphatic system arises as an extension of venous vessels in the embryo, little is known about
the role of circulating progenitors in the maintenance or development of lymphatic endothelium. Here, we investigated
whether hematopoietic stem cells (HSCs) have the potential to give rise to lymphatic endothelial cells (LEC).
Methodology/Principal Findings: Following the transfer of marked HSCs into irradiated recipients, donor-derived LEC that
co-express the lymphatic endothelial markers Lyve-1 and VEGFR-3 were identified in several tissues. HSC-derived LEC
persisted for more than 12 months and contributed to ,3–4% of lymphatic vessels. Donor-derived LECs were not detected
in mice transplanted with common myeloid progenitors and granulocyte/macrophage progenitors, suggesting that
myeloid lineage commitment is not a requisite step in HSC contribution to lymphatic endothelium. Analysis of parabiotic
mice revealed direct evidence for the existence of functional, circulating lymphatic progenitors in the absence of acute
injury. Furthermore, the transplantation of HSCs into Apc
Min/+ mice resulted in the incorporation of donor-derived LEC into
the lymphatic vessels of spontaneously arising intestinal tumors.
Conclusions/Significance: Our results indicate that HSCs can contribute to normal and tumor associated lymphatic
endothelium. These findings suggest that the modification of HSCs may be a novel approach for targeting tumor metastasis
and attenuating diseases of the lymphatic system.
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Introduction
Functional lymphatics are critical for extracellular fluid
homeostasis, fat absorption from the gut and immune function
[1,2,3]. Lymphatic vessels also provide a route for leukocytes in
tissues to re-enter venous circulation, and thus play an active role
in acute and chronic inflammation. Importantly, tumor induced
lymphangiogenesis has recently been shown to actively potentiate
the metastatic spread of some cancers [2,4,5,6]. Despite these
important roles in normal and pathologic processes, only recently
have we begun to gain an understanding of how the lymphatic
system is maintained.
In the embryo, lymphatic endothelium arises from existing
venous endothelial cells [7]. Although they share a common
origin, lymphatic and venous endothelia are quite distinct at the
morphological, functional and molecular levels. For example, in
contrast to venous endothelium, lymphatic endothelium lacks a
continuous basement membrane, is not surrounded by pericytes,
and is largely devoid of vascular smooth muscle cell coverage [2].
Moreover, lymphatic endothelium highly expresses a number of
proteins that are absent or expressed at relatively low levels in
blood vascular endothelium. These lymphatic markers include the
CD44 homolog, lymphatic endothelial hyaluronan receptor -1
(Lyve-1), vascular endothelial growth factor receptor-3 (VEGFR-
3), Podoplanin and the homeobox transcription factor Prox1 [3].
The mechanisms by which new lymphatic vessel growth occurs
in adults (i.e., lymphangiogenesis) and by which existing lymphatic
vessels are repaired or remodeled after injury are currently not
known. Previously, we [8,9] and others [10,11] demonstrated that
adult bone marrow-derived, hematopoietic stem cells (HSCs) give
rise to functional vascular endothelial cells in the mouse at the
clonal level through differentiation in the absence of cell fusion.
Furthermore, we [12] and others [13] have shown that in humans,
hematopoietic derived cells contribute to both normal and tumor
vascular endothelium. Taken together, these results indicate that
adult bone marrow-derived hematopoietic stem cells may serve as
a source of vascular endothelial progenitor cells. These findings
raise the question of whether HSCs contribute to the maintenance
and function of normal lymphatic endothelium (LEC).
Here we show that adult hematopoietic stem cells can give rise
to LECs that integrate into lymphatic vessels in normal tissues and
in newly formed tumors. By contrast, myeloid progenitors do not
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hematopoietic contribution to lymphatic endothelium can be
mediated by circulating cells in the absence of acute radiation
injury. These findings suggest a role for hematopoietic cells in the
maintenance of lymphatic homeostasis.
Results
Evaluation of lymphatic vessel-specific markers
We focused most of our studies on mouse liver, specifically in
the portal triad area (which contains the portal vein, hepatic
artery, bile ducts, and small lymphatic vessels), because of the high
frequency and distinctive morphology of the lymphatic vessels in
this tissue. In order to distinguish lymphatic from blood vascular
endothelial cells, we evaluated expression of the lymphatic markers
Lyve-1 [14] and VEGFR-3 [15], in combination with the pan-
endothelial cell marker CD31/PECAM-1, and the blood vessel
endothelium-specific marker von Willebrand factor (vWF). As
Prox1 is expressed by hepatocytes throughout the adult mouse
liver [16], it was not utilized as a marker in our studies.
In the portal triad, we readily identified vessels that were strongly
immunoreactive for Lyve-1 (Fig. 1a) and co-expressed CD31
(Fig. 1b,c). By contrast, the portal vein (Fig. 1a,c) and other large
blood vessels completely lacked Lyve-1 expression. Consistent with
these findings, lymphatic vessels expressed VEGFR-3, but not vWF,
whereas portal veins expressed vWF, but not VEGFR-3 (Fig. 1 d–f).
As endothelial cells are often closely apposed to other cell types, it is
critical to distinguish them from neighboring cells. Lymphatic
vessels in the portal triad are devoid of smooth muscle actin (a-
SMA) expressing pericytes and vascular smooth muscle, unlike
blood vessels which are closely associated with these cell types
(Fig. 1g). Macrophages are also known to closely associate with
endothelial cells and express a number of endothelial cell markers.
Notably, the Lyve-1 antigen is expressed by stabilin-1
+, F4/80
+,
CD11b
+macrophagesintumorsand inwoundhealing models [17].
Therefore staining of Lyve-1 and F4/80
+ was employed to
determine whether a similar Lyve-1
+ macrophage population exists
in the portal triad region of healthy mice during steady state
conditions. We readily detected F4/80
+ cells, however none co-
expressed Lyve-1 (Fig. 1h). Taken together, our results confirm that
lymphatic endothelial cells can be clearly distinguished from blood
vessel endothelium, macrophages and pericytes by their morphol-
ogy, location, high levels of Lyve-1 and VEGFR-3 expression, and
absence of macrophage (F4/80), pericyte (a-Sma) and endothelial
(vWF) cell –specific marker expression.
Adult hematopoietic stem cells contribute to lymphatic
endothelium in multiple tissues
In order to evaluate the potential of adult hematopoietic stem
cells to differentiate into lymphatic endothelium, between 200 to
500 sorted GFP
+ c-kit
+, Sca-1
+, lineage
- (KSL) cells, hereafter
referred to as HSCs, were transplanted into lethally irradiated
(1200 cGy) recipient mice (Fig. 2a) as previously described [8].
Donor-derived cells in the peripheral blood and bone marrow of
the chimeric mice were detected by flow cytometry, with GFP
+
cells comprising between 80–90% of nucleated hematopoietic cells
(data not shown). From one to 20 months following HSC
transplantation, recipient tissues were harvested and evaluated
for the presence of donor-derived lymphatic endothelium defined
as GFP
+ and Lyve-1
+ and/or VEGFR-3
+, CD45
2 and F4/80
2.
As shown in Figure 2b–e, CD45
2 and F4/80
2 GFP
+ donor
cells were readily detected in the lymphatic endothelium. Co-
localized expression of endothelial markers in individual donor-
derived GFP
+ LECs was confirmed by confocal microscopy
(Fig. 2c–e). As it is recognized that bone marrow derived cells also
give rise to vascular pericytes and perivascular supportive cells
[18], we assessed a-SMA expression in donor-derived cells
incorporated into lymphatic vessels. No a-SMA co-expression
was detected in these GFP
+, Lyve-1
+ cells confirming their
lymphatic endothelial identity (Fig. 2f, g).
The persistence of the HSC contribution to lymphatic
endothelium was determined by evaluating lymphatic vessels for
the presence of donor-derived LECs at one month and at greater
than one year after transplantation. At these time points, we found
a mean of 2.4%60.8% of lymphatic vessels and 3.2%61.4% of
lymphatic vessels in the portal triad contained GFP+ LECs (Fig. 2i).
These donor-derived cells expressed the LEC marker VEGFR-3
(Fig. 2h), demonstrated normal morphology and formed patent
vessels whose lumens contained the occasional leukocyte (data not
shown). Taken together these findings demonstrate the durable
integration of donor HSC-derived LEC into lymphatics.
Figure 1. Lymphatic endothelial cells are readily distinguished
from vascular endothelial cells. The portal triad region of mouse
liver was analyzed for the expression of lymphatic (Lyve-1, VEGFR-3) and
vascular (CD31, vWF) endothelial cell markers, a macrophage marker
(F4/80) and a pericyte/smooth muscle marker (a-SMA). (a) Lymphatic
endothelial cells are Lyve-1
+ (red). (b) Both portal veins and lymphatic
vessels express CD31 (green). (c) Merged image of a and b. Double
positive CD31
+, Lyve-1
+ cells are yellow. d) VEGFR3
+ lymphatic
endothelial cells (red), do not express (e) the blood vessel endothelial
marker vWF (green). (f) Merged image of d and e. (g) Lyve-1
+ lymphatic
vessels (red) do not express the pericyte marker a-SMA (green) or (h)
the macrophage marker F4/80 (green). (DAPI stained nuclei are blue.
PV=portal vein, LV=lymphatic vessel, BD=bile duct; scale bars:
20 mm).
doi:10.1371/journal.pone.0003812.g001
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hematopoietic stem cells contribute to lymphatic endothelium in
other tissues, the stomach and intestine were investigated in long-
term HSC- reconstituted recipients (Fig. 3). A mean of
1.0%60.7% intestinal lymphatic vessels and 1.4%60.7% gastric
lymphatic vessels were engrafted with GFP
+ HSC-derived LECs
(Fig. 3e). Although the density of lymphatic vessels in the kidney is
low, HSC-derived LECs were detected (data not shown). Thus
HSCs have the potential to give rise to lymphatic endothelium in a
wide range of tissues, including those of both endodermal and
mesodermal origin.
Long-term engraftment of self-renewing HSC with LEC
potential
In order to directly measure the self-renewal capacity of cells
with lymphatic endothelial progenitor activity, serial transplanta-
tion studies were performed (Fig. 4a). At 8 months after HSC
transplant, whole bone marrow was collected from primary
recipients and transplanted into secondary, irradiated recipients.
Analysis of the peripheral blood demonstrated high levels of donor
HSC-derived, multi-lineage hematopoietic reconstitution (Fig. 4b),
confirming that bona-fide HSCs had been transplanted into
Figure 2. HSC-derived lymphatic endothelial cells stably
incorporate into lymphatic vessels. a) Six months following
transplantation of GFP
+, c-kit
+/Sca-1
+/lin
2 hematopoietic stem cells,
recipient liver was examined for donor-derived lymphatic endothelium,
hematopoietic cells, vascular smooth muscle and pericytes. (b) Low
power view of donor-derived, GFP+ (green) cells (box) associated with a
Lyve-1+ (red) lymphatic vessel (LV). (c–e) High magnification, confocal
images of the boxed area shown in b. The arrow indicates a donor-
derived lymphatic endothelial cell that is (c) GFP+ (green), (d) CD45
2
and F4/80
2 (absence of magenta), and is (e) Lyve-1+ (red). Nuclei are
stained with DAPI (blue). The arrowhead indicates a donor-derived
(green), CD45
+ and/or F4/80
+ (magenta) hematopoietic cell next to the
lymphatic vessel. Cells in which GFP overlaps with DAPI and CD45 and/
or F4/80 appear white (green+ blue+ magenta=white). Cells in which
GFP overlaps with Lyve-1 (red+ green=yellow) and DAPI appear white
(red+ green+ blue=white). (f & g) a-SMA expression (grey) distinguish-
es blood vessels (BV) from lymphatic vessels (LV). (f) Donor-derived cells
(green) near a blood vessel surrounded by a-SMA
+ pericytes (grey). The
arrow points to a (g) Lyve-1+ (red) donor-derived cell within a lymphatic
vessel. (h) A merged image showing a donor-derived GFP+ (green),
VEGFR3+ (red) lymphatic endothelial cell in a lymphatic vessel. (i)
Frequency of liver lymphatic vessels containing donor-derived endo-
thelial cells 1 month to .12 months after HSC transplantation. Each
symbol represents an individual HSC recipient. The horizontal line
indicates the average of each group. (Panels b–e, scale bars are 5 mm.)
doi:10.1371/journal.pone.0003812.g002
Figure 3. HSC-derived lymphatic endothelial cells are detected
in gastrointestinal tissues. (a & b) Bright field images of (a) gastric
and (b) gut tissue containing Lyve-1
+ (brown, DAB-stained) lymphatic
vessels. Sections are counterstained with hematoxylin (purple). (c)
Merged image of a donor-derived (green), Lyve-1
+ (red) lymphatic
endothelial cell in the stomach. (d) Merged image of donor-derived
(green), VEGFR-3+ (red) lymphatic endothelial cell in the gut. DAPI
stained nuclei are blue. (e) Frequency of lymphatic vessels in the
stomach and gut containing donor-derived endothelial cells after HSC
transplantation. Each symbol represents an individual HSC recipient.
The horizontal line indicates the average for each group. (LV=Lym-
phatic Vessel, M=Muscle. Scale bars: a: 50 mm; b: 20 mm; c & d: 5 mm).
doi:10.1371/journal.pone.0003812.g003
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secondary recipients showed clear evidence of donor cell
engraftment (Fig. 4c). Donor-derived vascular EC were detected
in neighboring liver tissue sections (Fig. 4d), consistent with our
previously reported findings [8]. These serial transplantation
studies demonstrate that the progeny of donor HSC within the
bone marrow have self renewal potential in terms of their capacity
to contribute to both blood lineages and lymphatic vascular
endothelium.
Lymphatic endothelium does not arise from a common
myeloid progenitor
The ontogenic relationship between venous and lymphatic
endothelium raises the possibility that in the adult, a common,
circulating bone-marrow derived progenitor might give rise to
both lymphatic and vascular endothelial cells. We have recently
shown that transplanted common myeloid progenitors (CMPs) and
granulocyte/monocyte progenitors (GMPs) contribute to vascular
endothelium at frequency similar to that of isolated HSCs [9].
Therefore, we tested whether either of these progenitor popula-
tions contributed to lymphatic endothelium in the portal triad area
of transplanted mice. Lethally irradiated mice were transplanted
with 5–10610
3 GFP+ CMPs or GMPs and analyzed 2–3 weeks
following transplantation. Although we examined .10,000
lymphatic vessel cross sections from the portal triad region of
CMP and GMP recipients, we did not detect any donor-derived
lymphatic endothelium. These findings suggest that unlike HSC-
derived blood endothelium progenitors, HSC-derived lymphatic
progenitors are distinct from the myeloid lineage.
HSCs contribute to tumor lymphatic endothelium
Lymphatics are known to be an important contributor to tumor
metastasis. To address the question of whether HSCs are capable
of contributing to tumor associated lymphatics, we utilized the
Multiple Intestinal Neoplasia (Min) mouse model for intestinal
tumorigenesis. These mice harbor a mutated Apc gene [19] and
spontaneously develop multiple intestinal adenomas within the
first 8–10 weeks of life [20,21]. Min mice were irradiated (1200
cGy) and then transplanted with GFP+ HSC cells from Y01 GFP-
expressing mice at 5 weeks of age. Six weeks after transplantation,
intestinal tumors were harvested and evaluated for endothelial
cells that co-expressed CD31 and Lyve-1. Consistent with our
findings in normal tissues, blood vessels within these tumors
expressed CD31, whereas lymphatic vessels expressed both CD31
(data not shown) and Lyve-1(Fig. 5a,b). In all adenomas examined,
we found that donor HSC derived EC also incorporated into the
tumor associated lymphatic vessels (Fig. 5c–e). The chimeric
lymphatic vessels we observed in the Min mice have a normal,
open vessel morphology consistent with the relatively well
differentiated state of Min adenomas. Moreover, we detect
mononuclear leukocytes within the lymphatic vessel lumen
(Fig. 5d). Together, these data suggest that HSC-derived LEC
are incorporated in functional lymphatic vessels in these tumors.
Contribution of donor-derived cells to lymphatic
endothelium in the absence of tissue damage
Ionizing radiation is typically employed to induce myeloablation
and enhance hematopoietic cell engraftment. However, in
addition to ablating the hematopoietic cells, radiation exposure
Figure 4. Lymphatic and vascular endothelial potential of self-renewing of HSCs. (a) Secondary transplantation scheme. (b) Flow
cytometry analysis of multi-lineage hematopoietic cells in the peripheral blood of secondary recipients. Donor-derived (GFP+) B220 (B-cells), CD3 (T-
cells), Mac1/Gr-1(myeloid cells) are shown. (c) Merged image of donor-derived (green), Lyve-1
+ (red), CD45
2 (absence of magenta) lymphatic
endothelial cells (arrows). (d) Merged image of donor-derived (green), vWF+ (red), CD45- (absence of magenta) vascular endothelial cell (arrow). (DAPI
stained nuclei are blue in c,d. LV=lymphatic vessel, BV=blood vessel; scale bars: 5 mm).
doi:10.1371/journal.pone.0003812.g004
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This raises the question of whether lymphatic damage might be a
prerequisite for the contribution to lymphatic endothelium in our
transplant recipients. To address this issue, we employed a
parabiosis model and determined whether donor-derived cells can
contribute to LECs in the absence of radiation exposure.
Specifically, GFP expressing and wild-type mice were surgically
joined for 12 weeks, separated, and then analyzed 4–6 months
later by flow cytometry and immunohistochemistry (Fig. 6a). As
previously reported, wild- type parabiotic mice displayed stable
donor-derived (GFP+) multi-lineage hematopoietic reconstitution
of the peripheral blood [9,23]. Circulating, donor-derived B cells,
T cells, and myelomonocytic cells were found at the expected
frequencies in the parabiotic mice (Fig. 6b). Donor-derived GFP
+,
Lyve-1
+, CD45
2, F4/80
2 lymphatic endothelial cells and GFP+
hematopoietic cells were found in the livers of the parabiotic
partners (Fig. 6c–f). In addition, serial transplantation studies of
BM harvested from wild-type parabiotic mouse partners con-
firmed that self-renewing HSCs from the original parabiotic donor
were present (data not shown).
Discussion
In the present study, we show that highly purified, transplanted
HSCs can give rise to lymphatic endothelial cells that integrate
long-term into lymphatic vessels in many tissues, including the
liver, kidney, stomach and gut. Moreover, we demonstrate that
HSCs can contribute to LECs associated with intestinal epithelial
tumors. Importantly, radiation-induced lymphatic endothelial cell
injury is not required for circulating progenitor cells to generate
lymphatic endothelium. Our data also demonstrate HSC-derived
lymphatic potential is not exclusively found within the myeloid
lineage, as transplanted purified myeloid progenitors do not give
rise to LECs in vivo. Together, these data suggest that the
hematopoietic system can give rise to LECs during steady state
conditions, and that this is at least in part mediated by a circulating
lymphatic endothelial cell progenitor that is distinct from
previously characterized HSC-derived blood vascular endothelial
progenitors.
Historically, the formation of new blood vessels (angiogenesis)
and lymphatic vessels (lymphangiogenesis) in adults was viewed as
driven by the proliferation and remodeling of existing endothelial
cells. Recent reports by several groups suggest that bone marrow
(BM)-derived hematopoietic cells also have the capacity to
contribute to varying degrees to blood vascular endothelium in
mouse [8,9,10,11,24,25,26,27] and humans [12,13]. Observations
such as these have led to the idea that postnatal angiogenesis is
driven at least in part by BM-derived endothelial progenitor cells
(EPCs), which integrate into and function within neovessels
(reviewed by [28]). However, the concept of BM-derived cells
with the capacity to produce functional, bona fide ECs is still quite
controversial, as some groups have found no evidence to support
their existence [29,30,31,32,33,34].
In the embryo, LECs are derived from committed venous
endothelial cells [7]. However, the origin of adult LECs and their
relationship to hematopoietic cells in newly formed lymphatic
vessels is controversial. That HSCs are at least one source of
lymphatic endothelium is supported by the isolation of hemato-
poietic cells with LEC potential in vitro [35] and the incorporation
of BM- derived cells into lymphatic endothelium [36,37] as well as
into the endothelial cell population at the junction between venous
and lymphatic vessels [38]. However, others have found no
evidence of BM-derived cell incorporation into lymphatics in their
experimental models [39].
It is presently unclear why there is such a disparity in the
detection of bone marrow contribution to LEC outcomes. One
possibility is that vastly different experimental methods are used to
induce lymphangiogenesis, including localized cytokine expression,
injection of different tumor cell lines, induction of inflammation and
preconditioning with irradiation. Moreover, lymphatics within
distinct anatomical locations were analyzed in each of these studies.
As there is little known about the molecular heterogeneity of
lymphatic endothelium in different organs [2], it is possible that
tissue-specific differences in lymphatic induction, growth and repair
mechanisms govern the LEC potential of BM-derived cells. Our
results support the existence of an HSC-derived lymphatic
progenitor that can contribute to a small but significant fraction
of lymphatic endothelial cells in the liver, gut and kidney, as well as
to lymphatics in spontaneous intestinal adenomas. Moreover, our
parabiosis data suggest that neither major injury nor ectopic
cytokine induction is necessary for this process to occur.
The methodology used to analyze endothelium is critical for
accurately detecting bona fide donor-derived endothelial cells. It
has been suggested that perivascular cells, such as macrophages
and pericytes, adjacent to vascular endothelial cells may be
misidentified as endothelial cells using conventional histological
analysis [32,33]. By logical extension, this argument could be
applied to analysis of donor-derived LECs. Importantly, our Z-
stack analysis clearly identifies HSC-derived LECs (Fig 2b–e) that
do not coexpress macrophage or pericyte markers. Furthermore,
unlike vascular endothelium, lymphatic vessels are devoid of
pericytes, thereby eliminating these cells as a source of false
positive, donor-derived LECs.
Figure 5. HSC-derived lymphatic endothelial cells incorporate
into tumor lymphatics. Following transplantation of HSCs into Min
mice, spontaneously developing intestinal tumors were examined for
donor-derived (GFP+), Lyve-1
+, CD45
2, F4/80
2 lymphatic endothelial
cells. (a) Hematoxylin and eosin (H&E) staining of a tumor in a Min
mouse. (b) High magnification of the boxed area in panel a
demonstrating Lyve-1+ (red) lymphatic vessels within the tumor. (c)
Merged image of a donor-derived (green), Lyve-1+ (red) lymphatic
endothelial cell (arrow) and a donor-derived hematopoietic cell (arrow
head). (d) The donor-derived hematopoietic cell expresses CD45 and/or
F4/80 (magenta), whereas the donor-derived LEC does not. (e) Merged
image of c and d (green+ blue+ magenta=white). (DAPI stained nuclei
are blue in b–e. Scale bars: a: 500 mm; b: 200 mm, c–e: 5 mm)
doi:10.1371/journal.pone.0003812.g005
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physical and functional relationship between myeloid cells and
endothelium has been observed by many investigators. Tissue
macrophages provide paracrine factors that promote endothelial
cell proliferation and also serve as scaffolds for neovessels
[reviewed by 1,40,41,42]. Myeloid cells also directly contribute
to vascular endothelium [9] and lymphatic endothelium [36,43].
Interestingly, tissue macrophages can transdifferentiate into LECs
in vivo, in both inflammatory [36] and wound healing [43]
settings. These transient populations of macrophage-derived cells
co-express macrophage markers (such as F4/80, used in our
studies) and LEC markers. The hypotheses that bone marrow-
derived myelomonocytic cells have a strong, non-cell autonomous,
cytokine mediated proangiogenic effect and that myelomonocytic
progenitor cells can give rise to endothelium are certainly not
mutually exclusive. Notably, organ-specific VEGF expression
induces angiogenesis by recruiting BM-derived circulating cells,
the majority of which are perivascular myeloid cells. In addition, a
small fraction of BM-derived cells also incorporate into neovessels.
[26]. The extent to which these complementary proangiogenic
functions of myelomonocytic cells contribute to normal and
pathologic neoangiogenesis remains to be determined.
Given the precedent that myelomonocytic cells can give rise to
both vascular ECs and LECs, it is tempting to speculate that all
HSC-derived LECs must arise through a myeloid intermediate.
However, our analysis of lymphatic vessels within the portal triads
of CMP and GMP recipient mice does not support this possibility.
We found no evidence of donor cell contribution to lymphatic
endothelium in recipients in which we readily detected blood
vessels that contained donor CMP- or GMP-derived endothelial
cells. Our findings suggest that HSC commitment to the myeloid
lineage is not a requisite step in the generation of HSC-derived
lymphatic endothelium. However, whether CMPs and GMPs can
directly contribute to lymphatic endothelium in other tissues or
indirectly contribute to lymphangiogenesis in the setting of tissue
inflammation and repair via perivascular myelomonocytic cells
remains to be determined.
A close relationship between HSC and lymphatic endothelium
has also been demonstrated in a recent study by Massberg and
colleagues [44]. They showed that bone marrow derived HSCs
with self-renewing activity are present in the lymph of the thoracic
duct. Furthermore, their analysis of parabiotic mice revealed that
circulating HSCs enter blood circulation and then egress into
lymphatics. Based on our findings, we postulate that HSCs present
in the lymphatic system may also differentiate into LECs, or
alternatively, into a population of functional LEC precursors.
It has been long appreciated that tumor spread into regional
lymphatics is an important mechanism of metastasis. Tumor-
associated lymphangiogenesis increases lymphatic tumor metasta-
sis in a number of experimental models [1,2], although fully
Figure 6. Parabiosis reveals the presence of functional circulating lymphatic progenitors in the absence of acute tissue injury. (a)
Non-irradiated wild type mice were surgically joined (parabiosed) with GFP partners. After 12 weeks, mice were separated for between 4–6 months
then lymphatic vessels were analyzed. (b) Separated, individual mice displayed stable, donor-derived multi-lineage hematopoietic reconstitution of
the peripheral blood. (c–f) Analysis of donor-derived cells in and near a lymphatic vessel. A donor-derived LEC (arrow), a donor-derived hematopoieitc
cell within the lymphatic vessel (arrow head), and a donor-derived hematopoietic cell adjacent to the lymphatic vessel (asterisk) are shown. DAPI
stained nuclei are blue. Scale bars: 5 mm. (c) Donor-derived, GFP+ cells (green). (d) CD45 and F4/80 distinguishes hematopoietic (magenta, arrowhead
and asterisk) from non-hematopoietic (arrow) donor-derived cells. (e) Lyve-1+ (red) reveals the presence of a donor-derived LEC (arrow). (f) Merged
image of c–e.
doi:10.1371/journal.pone.0003812.g006
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metastatic spread to regional lymph nodes [45]. Our findings
demonstrate that HSC derived LEC are incorporated into tumor
associated lymphatic vessels. Future studies will determine whether
HSC-derived cells potentiate lymphangiogenesis in tumors and
whether targeting HSCs may be a feasible approach for
attenuating lymphatic system mediated tumor metastasis.
Materials and Methods
Mice
Male donor (8–12 weeks old) C57BL/6-TgN (ACTBEGFP)
YO1 mice were harvested for donor cells. Female C57Bl6
recipient mice (8–12 weeks old), and 5-week-old male Min mice
[19] were used as recipients. Mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and maintained in a
breeding colony in the animal care facility at the Oregon Health &
Science University. All procedures were approved by the
institutional animal care and use committee of the Oregon Health
& Science University.
Isolation of HSCs and myeloid progenitors
Donor BM was prepared as previously described by Bailey et al
[8]. All antibodies were purchased from BD Pharmingen (San
Diego, CA) unless otherwise indicated. For KSL isolation, single-
cell suspensions of BM were labeled with antibodies to c-kit-
allophycocyanin (APC), Ly6 AE (Sca-1) -Biotin with StreptAvidin-
PharRed and a phycoerythrin (PE)-conjugated lineage mixture
(B220, CD3, CD5, CD4, CD8, Mac-1, Gr-1, Ter119). HSCs were
enriched to homogeneity by double sorting c-kit
+/sca-1
+/lineage-
negative (lin
2) cells using a fluorescence-activated cell sorter
(FACS) Vantage. Myeloid progenitors were isolated as described
previously [9]. Bone marrow cells were labeled with a PE-
conjugated lineage mixture (B220, CD3, CD4, CD8, Gr-1,CD19,
IgM [e-biosciences, San Diego, CA], and Ter119) and the
antibodies IL-7Ra-PE (e-biosciences), Ly6AE-PE, c-kit-APC-
Cy7(e-biosciences), CD34-FITC, and FccRII/III-APC (e-biosci-
ences). Purified progenitors were obtained by double-sorting of IL-
7Ra
2 Lin
2Sca-1
2c kit
+CD34
+FccRII/III
lo (CMP) and IL-7Ra
2
Lin
2 Sca-1
2 c- kit
+ CD34
+ FccRII/III
hi (GMP) populations.
Dead cells were excluded by a combination of scatter gates and
propidium iodide staining.
Transplantation studies
Recipient mice were treated with 1200 cGy of lethal irradiation
in 2 equal doses of 600 cGy delivered 3 hours apart. The indicated
number of donor cells was injected intravenously into the retro-
orbital plexus. Recipients received antibiotic water for one month
after transplantation (neomycin sulfate at 1.1 g/L and polymyxin
B sulfate at 167 mg/L).
Parabiosis
Parabiotic pairs of 6- to 12-week-old age- and weight-matched
female WT and Y01 GFP+ mice were made as previously
described [9]. Each parabiotic recipient was given recombinant
human granulocyte colony-stimulating factor (250 mg/kg s.c.) for
4 days at 2–3 weeks after surgery. Peripheral blood was collected
and analyzed by flow cytometry to evaluate donor chimerism
through cross-circulation. Mice were separated 12 weeks after
surgery, and peripheral blood and liver were analyzed 4–6 months
later.
Hematopoietic Engraftment
Peripheral blood leukocytes were obtained after erythrocyte
depletion by sedimentation in 3% dextran (Amersham Pharmacia,
Uppsala, Sweden) and hypotonic lysis. Multi-lineage hematopoi-
etic engraftment was analyzed with the antibodies CD45.2-FITC
(donor), CD45.1-PE (host), and the lineage markers Mac1-APC,
Gr1-APC, B220- APC, and CD3-APC as previously described
[46].
Immunohistochemistry
Recipient mice were sacrificed between 1 and 12 month after
transplantation. Liver, kidney, stomach and gut were fixed in 4%
paraformaldehyde for 4 hours, washed, dehydrated in 30%
sucrose, then cryopreserved in optimal cutting temperature
(OCT). In some instances, tissues were fixed formaldehyde with
zinc buffer (Z-fix; Anatech, Battle Creek, MI), embedded in
paraffin and sectioned. Five micrometer tissue sections were
incubated overnight at 4uC with rabbit anti-LYVE-1 (1:800;
Upstate Biotechnology, Lake Placid, NY), rat anti-CD31 (1:50; BD
Pharmingen) or rat anti-VEGFR3 (1:25; BD Pharmingen),
followed by a Cy3 conjugated secondary antibody (Chemicon,
Temecula, CA). To differentiate donor-derived hematopoietic
cells, we double stained the sections with rat anti-CD45 (1:50; BD
Pharmingen) and rat anti-F4/80 (1:100; Serotec, Raleigh, NC),
followed by Alexafluor 647 chicken anti-rat (Invitrogen-Molecular
Probes, Eugene, OR). The nuclei were counterstained with DAPI
(4,6 diamidino-2-phenylindole). Tyramide signal amplification
(NEN Life Science, Boston, MA) was employed to enhance
VEGFR-3 staining in paraffin sections, using the Cy3 tyramide
reagent. Rat IgG2a k or rat IgG2b k was used as a negative
control for CD31, CD45 and F4/80 antibody staining.
Image Analysis
Sections were examined and photographed with a Zeiss
Axiophot 200 microscope by using a true color AxioCam camera
and standard epifluorescence filters for fluorescein isothiocyanate
(FITC), Cy3, Cy5 and DAPI (Carl Zeiss, Jena, Germany). Images
were digitally combined using Axio Vision software (Carl Zeiss). Z-
stack images were obtained with a BioRad 1024 ES confocal laser
scanning microscope (BioRad, Hercules, CA) and analyzed using
Delta Vision deconvolution software (BioRad). A minimum of 100
liver lumen-containing lymphatic vessels (based on LYVE-1
staining) were counted per recipient mouse.
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